Shay Capital’s CRISPR Therapeutics CRSP Stock Holding History

Shay Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,261	Closed	-$852K	–	579
2021 Q2	$852K	Buy	+5,261	New	+$640K	0.1%	177

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Shay Capital's CRSP Position: Q3 2021 in Review

Shay Capital sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 5,261 shares — an estimated $852K sold.

Shay Capital first reported a position in CRSP in Q2 2021 and held it in 1 quarter. The position peaked at $852K in Q2 2021. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

Shay Capital reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
Shay Capital sold 5,261 CRISPR Therapeutics shares in Q3 2021, an estimated $852K.
Shay Capital first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 1 quarter.
Shay Capital's CRISPR Therapeutics position peaked at $852K in Q2 2021.
473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Shay Capital's 13F filing for Q3 2021, filed 15 Nov 2021.